BridgeBio Pharma, Inc. (BBIO) · Oct 29, 2026 · Earnings
Beat — Revenue $353.2M vs ~$293.5M consensus; EPS -$0.42 vs ~-$0.54
BridgeBio earnings beat Q3 expectations as Attruby revenue surged, though a one-time Bayer milestone inflated the headline result.
BridgeBio is moving from a single commercial product into a multi-launch biotech: Attruby is scaling in ATTR-CM while BBP-418, infigratinib, and encaleret approach regulatory decisions. Its prior-quarter setup already included three planned launches and substantial launch spending, so this report is mainly about execution and the size of the commercial ramp rather than a new strategic direction.
The quarter beat the published financial bar. Total revenue was $353.2 million versus a published consensus of roughly $293.5 million, while EPS was a $0.42 loss versus roughly a $0.54 loss expected.
| Figure | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Total revenue (Financial Highlights) | $353.2M | $120.7M | ~$293.5M |
| Net product revenue (Financial Highlights) | $253.3M | $108.1M | |
| Net loss per share (Income Statement) | -$0.42 | -$0.95 | ~-$0.54 |
| Loss from operations (Income Statement) | -$11.6M | -$145.2M | |
| Cash, equivalents and marketable securities (Balance Sheet) | $1.539B | $587.5M |
Attruby’s underlying commercial trend is the cleanest positive. U.S. Attruby revenue reached $253.2 million, up about $31 million sequentially and $145.2 million year over year; the company says the product gained first-line share and delivered another quarter of sequential growth. 〔0〕
The headline beat is partly one-time. License and services revenue included a $75.0 million Bayer sales milestone, meaning the near-break-even operating result is not yet a clean measure of recurring profitability. The core commercial engine improved, but BridgeBio is also spending heavily to prepare for multiple launches: quarterly SG&A rose $63.2 million and R&D rose $30.6 million.
The pipeline is advancing, but most of the regulatory story was already known. BBP-418 still has a November 27, 2026 PDUFA date, followed by infigratinib on February 4, 2027 and encaleret on May 8, 2027. The new information is mostly launch readiness, additional supporting data, and the start of RECLAIM-HP—not a change to the approval timetable.
Liquidity supports the launch plan, but it was bought with significant financing. Cash, cash equivalents, and marketable securities stood at $1.5 billion, while nine-month operating cash use was $312.6 million. That gives BridgeBio room to execute, but the balance sheet also reflects $933.9 million of preferred-stock proceeds, $632.5 million of new notes, $884.1 million of deferred royalty obligations, and $942.5 million of Series A preferred stock. The filing therefore improves funding visibility without making the business self-funding yet.
Bottom line: This was a real earnings beat, led by accelerating Attruby demand and better-than-expected revenue, but the quarter’s near-break-even profile was helped materially by a one-time Bayer milestone. The business story advances; the next genuinely new test is whether BBP-418 converts the prepared launch infrastructure into an FDA approval on November 27, 2026.
BBP-418 PDUFA decision, November 27, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!